Literature DB >> 9530544

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

G J Moyle1, B G Gazzard, D A Cooper, J Gatell.   

Abstract

In the absence of evidence that eradication of HIV from an infected individual is feasible, the established goal of antiretroviral therapy is to reduce viral load to as low as possible for as long as possible. Achieving this with the currently available antiretroviral agents involves appropriate selection of components of combination regimens to obtain an optimal antiviral response. In addition, consideration of a plan for a salvage or second-line regimen is required if initial therapy fails to achieve an optimal response or should loss of virological control occur despite effective initial therapy. Such a planned approach, based on consideration of the likely modes of therapeutic failure (viral resistance, cellular resistance, toxicity) could be called rational sequencing. Choice of therapy should never involve compromise in terms of activity. However, the choice of drug should also be guided by tolerability profiles and considerations of coverage of the widest range of infected cells, compartmental penetration, pharmacokinetic interactions and, importantly, the ability of an agent or combination to limit future therapeutic options through selection of cross-resistant virus. Available clinical end-point data clearly indicate that combination therapy is superior to monotherapy, with clinical and surrogate marker data supporting the use of triple drug (or double protease inhibitor) combinations over double nucleoside analogue combinations. Thus, 3-drug therapy should represent current standard practice in a nontrials setting. Treatment should be considered as early as practical, and may be best guided by measurement of viral load, with a range of other markers having potential utility in individualising treatment decisions. Therapeutic failure may be defined clinically, immunologically or, ideally, virologically, and should prompt substitution of at least 2, and preferably all, components of the treatment regimen. Drug intolerance may also be best managed by rational substitution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9530544     DOI: 10.2165/00003495-199855030-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  100 in total

Review 1.  The role of didanosine in the management of HIV-1 infection.

Authors:  B G Gazzard; G J Moyle
Journal:  Antivir Ther       Date:  1997-07

2.  Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Authors:  S L Spruance; A T Pavia; J W Mellors; R Murphy; J Gathe; E Stool; J G Jemsek; P Dellamonica; A Cross; L Dunkle
Journal:  Ann Intern Med       Date:  1997-03-01       Impact factor: 25.391

3.  Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Authors:  R T Davey; D G Chaitt; G F Reed; W W Freimuth; B R Herpin; J A Metcalf; P S Eastman; J Falloon; J A Kovacs; M A Polis; R E Walker; H Masur; J Boyle; S Coleman; S R Cox; L Wathen; C L Daenzer; H C Lane
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  A controlled trial of zidovudine in primary human immunodeficiency virus infection.

Authors:  S Kinloch-De Loës; B J Hirschel; B Hoen; D A Cooper; B Tindall; A Carr; J H Saurat; N Clumeck; A Lazzarin; L Mathiesen
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

5.  Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.

Authors:  S F LeLacheur; G L Simon
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

Authors:  H Jacobsen; M Hänggi; M Ott; I B Duncan; S Owen; M Andreoni; S Vella; J Mous
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

7.  Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

Authors:  M J Kozal; K Kroodsma; M A Winters; R W Shafer; B Efron; D A Katzenstein; T C Merigan
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

8.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

9.  Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients.

Authors:  F Luque; A Caruz; J A Pineda; Y Torres; B Larder; M Leal
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

10.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

View more
  9 in total

Review 1.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Nelfinavir: an update on its use in HIV infection.

Authors:  A Bardsley-Elliot; G L Plosker
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 4.  A risk-benefit assessment of HIV protease inhibitors.

Authors:  G J Moyle; B G Gazzard
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

Review 5.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 6.  Abacavir: a review of its clinical potential in patients with HIV infection.

Authors:  P S Hervey; C M Perry
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 7.  Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Authors:  M Barry; F Mulcahy; C Merry; S Gibbons; D Back
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 8.  Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

9.  When to Start Antiretroviral Therapy and What to Start With-- A European Perspective.

Authors:  Ferdinand W.N.M. Wit; Peter Reiss
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.663

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.